These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21917177)

  • 1. Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.
    Huet C; Ouedraogo A; Konaté I; Traore I; Rouet F; Kaboré A; Sanon A; Mayaud P; Van de Perre P; Nagot N
    BMC Public Health; 2011 Sep; 11():700. PubMed ID: 21917177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.
    Pialoux G; Quercia RP; Gahery H; Daniel N; Slama L; Girard PM; Bonnard P; Rozenbaum W; Schneider V; Salmon D; Guillet JG
    Clin Vaccine Immunol; 2008 Mar; 15(3):562-8. PubMed ID: 18184824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
    Ferradini L; Jeannin A; Pinoges L; Izopet J; Odhiambo D; Mankhambo L; Karungi G; Szumilin E; Balandine S; Fedida G; Carrieri MP; Spire B; Ford N; Tassie JM; Guerin PJ; Brasher C
    Lancet; 2006 Apr; 367(9519):1335-42. PubMed ID: 16631912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.
    Musoke PM; Mudiope P; Barlow-Mosha LN; Ajuna P; Bagenda D; Mubiru MM; Tylleskar T; Fowler MG
    BMC Pediatr; 2010 Aug; 10():56. PubMed ID: 20691045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
    Minidis NM; Mesner O; Agan BK; Okulicz JF
    J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.
    Kouanda S; Meda IB; Nikiema L; Tiendrebeogo S; Doulougou B; Kaboré I; Sanou MJ; Greenwell F; Soudré R; Sondo B
    AIDS Care; 2012; 24(4):478-90. PubMed ID: 22148973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and virological discordance among people living with HIV on highly active antiretroviral therapy in Tigray, Northern Ethiopia.
    Hailu GG; Wasihun AG
    BMC Infect Dis; 2021 Jun; 21(1):561. PubMed ID: 34118891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children.
    Singh R; Mukherjee A; Singla M; Das BK; Kabra SK; Lodha R
    Indian J Pediatr; 2017 Dec; 84(12):893-896. PubMed ID: 28875475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.